

David R Matthews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1930030/publications.pdf>

Version: 2024-02-01

9
papers

6,501
citations

1305906

8
h-index

1637695

9
g-index

9
all docs

9
docs citations

9
times ranked

8225
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2020, 22, 335-345.	2.2	54
2	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 530-539.	2.2	14
3	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 2199-2203.	2.2	5
4	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2019, 21, 188-193.	2.2	33
5	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes, Obesity and Metabolism, 2019, 21, 454-466.	2.2	129
6	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	2.2	173
7	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
8	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2255-2263.	2.2	71
9	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	13.9	5,629